XMT-1522 is currently investigated in the first-in-human phase 1b dose escalation and expansion trial in patients with advanced HER2-expressing (IHC ≥ 1+) breast cancer, gastric cancer and non-small cell lung cancer progressing on standard therapy (clinicaltrials.gov identifier: NCT02952729). Here, ERBB2 is linked to breast carcinoma.